Receptor bias: difference between revisions
Diff·revision 11 → 12·06:33, 20 Feb 2025
Difference between revision 11 and revision 12 of Receptor bias. 2 lines changed; the page grew by 281 bytes.
| Revision 11 — 13:52, 31 Jan 2025 LCellLeif (talk) distinguish the active and total forms of the hormone throughout 3,236 bytes +84 | Revision 12 — 06:33, 20 Feb 2025 TitrationTheo (talk) consistent en dashes in ranges 3,517 bytes +281 | ||
|---|---|---|---|
| 25 | Evidence in humans is indirect. The bias factors reported for marketed agonists have not been shown to predict clinical differences between them, and the clinical differences that exist are adequately explained by pharmacokinetics and dose.{{r|drucker2018}} | 25 | Evidence in humans is indirect. The bias factors reported for marketed agonists have not been shown to predict clinical differences between them, and the clinical differences that exist are adequately explained by pharmacokinetics and dose.{{r|drucker2018}} |
| 26 | 26 | ||
| + | 27 | [[Tirzepatide|Tirzepatide]] is reported to show cAMP-favouring bias at the GLP-1 receptor, and it also has a potency imbalance between the GIP and GLP-1 receptors. These are two different senses of "bias" and conflating them is a common error. See [[Tirzepatide]].{{r|jones2018}} | |
| + | 28 | ||
| 27 | == References == | 29 | == References == |
| 28 | {{reflist}} | 30 | {{reflist}} |